Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Respiratory Biologics Market, and What Factors Will Drive It?

In recent times, there has been a substantial increase in the size of the respiratory biologics market. It is projected to rise from $6.38 billion in 2024 to $7.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.1%. Factors such as escalating cases of respiratory illnesses, a surge in the implementation of personalized healthcare practices, a rise in global healthcare spending, enhanced awareness and diagnosis of respiratory conditions, and a growing older population suffering from respiratory issues have all contributed to this historical growth.

Anticipated to experience accelerated expansion in the coming years, the size of the respiratory biologics market is projected to surge to $13.51 billion in 2029 with a CAGR of 16.2%. Factors driving this growth throughout the forecast period encompass the heightened prevalence of COPD and asthma, the rising uptake of biologic therapies, the growth in R&D expenditure, escalating need for non-invasive drug administration, and broadening of reimbursement policies. The forecast period is also expected to witness some key trends such as the adoption of monoclonal antibodies for treating respiratory diseases, progress in biologic drug formulations and delivery methods, regulatory authorizations, strategic partnerships and acquisitions amongst significant players, and the amalgamation of artificial intelligence in the discovery and development of drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Respiratory Biologics Market?

The increase in air pollution is anticipated to drive the expansion of the respiratory biologics market. Air pollution, defined as the existence of detrimental substances including gases, particulate matter, and biological molecules in the Earth’s atmosphere, can have adverse effects on both human health and the environment. The surge in urbanization and industrialization is contributing to the increase in air pollution, causing elevated levels of pollutants emitted from factories, vehicles, and construction activities. Respiratory biologics are instrumental in battling the health implications of air pollution, offering targeted treatments that lower inflammation and enhance lung function in individuals subjected to airborne pollutants. For instance, the Environmental Protection Agency, a government agency based in the United States, disclosed in January 2025 that over 66 million tons of pollutants were discharged into the atmosphere in the United States in 2023. Furthermore, according to the United Nations Environment Programme, an environmental authority based in Kenya, in September 2022, air pollution leads to 7 million premature deaths every year, with 99% of the global population breathing in polluted air. Therefore, the increase in air pollution is propelling the expansion of the respiratory biologics market.

Which Key Market Segments Comprise the Respiratory Biologics Market and Drive Its Revenue Growth?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

Which Areas Are Leading Regions in the Respiratory Biologics Market Expansion Across the Globe?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theRespiratory Biologics Market Direction?

Prominent businesses in the respiratory biologics market are honing their focus on the development of inventive biologic treatments, including targeted immune therapies, for enduring respiratory ailments, with the aim of offering specialised care that mitigates inflammation and enhances lung capabilities. These therapies are geared towards managing the body’s immune response in an attempt to lessen pulmonary swelling and address breathing issues inherent in chronic lung conditions. For example, Sanofi S.A., a pharmaceutical entity based in France, made a public announcement in September 2024 that Dupixent (dupilumab) had been approved by the US Food and Drug Administration (FDA) as a supplementary maintenance treatment for adults suffering from poorly managed chronic obstructive pulmonary disease (COPD) with an underlying eosinophilic phenotype. This development was noteworthy as Dupixent earned the distinction of being the first biologically-derived medicine to receive authorization in the US for the treatment of this specific category of COPD patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

How Is the Respiratory Biologics Market Conceptually Defined?

Respiratory biologics are a class of targeted medications derived from living organisms used to treat chronic respiratory diseases. These biologics typically target specific molecules in the immune system, such as interleukins (IL-4, IL-5, IL-13) or immunoglobulin E (IgE), to reduce inflammation and improve breathing. Respiratory biologics are often prescribed for patients with severe, uncontrolled respiratory conditions that do not respond well to standard treatments like inhaled corticosteroids and bronchodilators.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23497

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model